• STAT+: Moderna says RSV vaccine worked, setting stage for competition with GSK and Pfizer

    14 days ago - By STAT

    Moderna's vaccine against the respiratory syncytial virus, or RSV, reduced the rate of lower respiratory disease in people over 60 in a Phase 3 trial, the company said Tuesday.
    The result will increase competition in a soon-to-be crowded market. The drug giants Pfizer and GlaxoSmithKline have already presented results for their RSV vaccines in older individuals, and have been preparing for what could be a brisk marketing battle. Continue to STAT+ to read the full story...
    Read more ...